# Genelux

Source: https://onco.cc/companies/genelux/  
OnCo record `genelux` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Genelux is a United States-based biotechnology company running 2 late-stage cancer trials of olvimulogene nanivacirepvec and Olvimulogene nanivacirepvec in ovarian cancer and non-small-cell lung cancer.

## Summary

Genelux, based in Westlake Village, CA, the United States, is a biotechnology company. Genelux is a biopharmaceutical company developing oncolytic immunotherapies based on a modified vaccinia virus platform. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing olvimulogene nanivacirepvec and Olvimulogene nanivacirepvec in ovarian cancer and non-small-cell lung cancer. The largest, NCT05281471 (Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)), plans to enrol 186 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Genelux Corporation
- Tags: ctgov-sponsor
- HQ: Westlake Village, CA
- Type: biotech
- Website: https://www.genelux.com

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Genelux_Corporation
- Official website: https://www.genelux.com
- ClinicalTrials.gov: trials led by Genelux: https://clinicaltrials.gov/search?lead=Genelux%20Corporation

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Olvimulogene nanivacirepvec](https://onco.cc/drugs/olvimulogene-nanivacirepvec/)
- trials: [Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)](https://onco.cc/trials/nct05281471/), [Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL ](https://onco.cc/trials/nct06463665/)

---
JSON: https://onco.cc/api/v1/entities/genelux.json